BRCA1 and cancer: Patients with germline BRCA1/2 mutant cancers who developed an early RDR and continued on therapy (because of RECIST PR or SD) had significantly shorter TTP and OS when compared to those who did not have RDR (225 vs 389 days, HR: 0.56, 95% CI 0.30-0.90, p=0.027, and 480 vs 860 days, HR: 0.49, 95% CI 0.30-0.90, p=0.01, respectively) (Figure 2C and 2D).